
Mentors and mentees include specialists in complex medical dermatology, pediatric dermatology, and procedural dermatology to diversify trial opportunities.
Maddi Hebebrand is an associate editor of Dermatology Times and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Mentors and mentees include specialists in complex medical dermatology, pediatric dermatology, and procedural dermatology to diversify trial opportunities.

Strong mentorship provides resilience for young clinicians navigating evolving challenges in practice.

Art Garfunkel raises awareness about psoriasis, sharing his journey and the impact of tildrakizumab treatment in a campaign for support and hope.

The randomized, placebo-controlled trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 150 healthy volunteers.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Oversight and endorsement from trusted clinicians were consistent patient requirements for integrating both AI and telemedicine.

Karen McGuire, PhD, discusses TAMES-02, a clinical trial evaluating TolaSure for Epidermolysis Bullosa Simplex.

Expanded prescribing rights for pharmacists could ease treatment delays and improve access for AD patients.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Orphan designation provides Soligenix with potential regulatory, financial, and exclusivity benefits as it develops SGX945.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A recent HS Summit hosted by UCB brought together clinicians and patient advocates to strengthen research and awareness efforts.

Explore how synthetic data revolutionizes CSU research, enabling smaller sample sizes and enhancing trial efficiency and inclusivity.

Explore innovative acne therapies, including bimekizumab, offering hope for treatment-resistant acne conglobata and improved patient outcomes.

Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.

The FDA warned Supergoop and Vacation Inc. for marketing unapproved mousse sunscreens.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.

Vitiligo significantly influences patients' quality of life, affecting major life decisions and increasing perceived stigma.

Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.

New insights reveal that those with low BSA involvement often face significant disease burdens, challenging traditional treatment criteria.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

Explore the complexities of chronic hand eczema, its impact on quality of life, and emerging treatment options in this insightful review.

BioMendics initiates TAMES-02 trial for TolaSure, a groundbreaking therapy targeting the root cause of Epidermolysis Bullosa Simplex, offering new hope.

The drug’s approval in August 2025 follows robust efficacy and safety results from the DELTA 1, 2, and 3 clinical trials.